Clinical Trials

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06561074 2026-03-16

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

22 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07387471 2026-03-16

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

14 enrolled

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT05963074 2026-03-13

TAILOR

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06510309 2026-03-13

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

33 enrolled

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07218510 2026-03-13

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

33 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04128501 2026-03-06

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

100 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05268003 2026-03-05

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

26 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04802590 2026-03-04

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

194 enrolled

Lymphoma, Mantle-Cell

NCT06522386 2026-03-02

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

NCT03609593 2026-02-25

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Phase 2 Completed

42 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05650723 2026-02-25

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06524375 2026-02-25

BRAVE

118 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04169737 2026-02-24

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02756897 2026-02-19

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

234 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05336812 2026-02-19

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

52 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06466122 2026-02-19

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02846623 2026-02-17

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03946878 2026-02-17

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

32 enrolled

Lymphoma, Mantle-Cell

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05677919 2026-02-12

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

72 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT04895436 2026-02-09

ReVenG

75 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03513562 2026-02-06

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

28 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04560322 2026-02-04

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04285268 2026-01-30

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04419519 2026-01-29

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

81 enrolled

Phase 2 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07024706 2026-01-21

MAVRiC

80 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00501826 2026-01-07

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

160 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03708003 2025-12-30

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Phase 2 Terminated

30 enrolled

Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

110 enrolled

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03467867 2025-12-24

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

25 enrolled

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07154264 2025-12-24

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06387121 2025-12-17

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

53 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03567876 2025-12-08

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Phase 2 Completed

141 enrolled

Lymphoma, Mantle-Cell

NCT05099471 2025-11-28

VIWA-1

80 enrolled

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT03766763 2025-11-26

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

82 enrolled

Leukemia, B-Cell

NCT05464836 2025-11-26

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Phase 2 Terminated

2 enrolled 10 charts

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

90 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04941716 2025-11-19

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07231952 2025-11-17

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06967610 2025-11-06

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05529069 2025-10-24

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

30 enrolled

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05951959 2025-10-21

TrAVeRse

108 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 2 Completed

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05388006 2025-10-14

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07199855 2025-09-30

Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT03824483 2025-09-23

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

230 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07159620 2025-09-08

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

27 enrolled